Skip Navigation Menu
Government of Ontario Central Web Site Ontario Ministry of Health and Long-Term Care
Return to Home Page Government of Ontario Central Web Site Contact us for questions and comments Site map Version française de cette site web
Information Channels Public Information Health Care Providers News Media Text Only Version
Index Health Care Providers Section
Formulary Downloads
O P D P   H O M E
Plan to Reform Ontario’s Drug System
Legislation
Formulary
Publicly Funded Drug Programs
Executive Officer Communications
Drug Submissions
· Ontario Guidelines for Drug
  Submission and Evaluation

· Improving Patient Access
  to Drugs: Rapid Review
  Process

· Single Monthly Formulary
  Process

· Off-Formulary
  Interchangeability

· Ontario Guidelines for
  Economic Analysis of
  Pharmaceutical Products

· Submission Guidelines for
  Oncology Drugs

· Inter-Provincial Joint
  Oncology Drug Review
  Process

· Submission Guidelines for
  Diabetic Testing Agents

· Submission Guidelines for
  Nutrition Products

· Drug Submissions
  Guidelines

· Price Increase Requests
How Drugs Are Approved
Councils
Drug Innovation Fund
MedsCheck
Glossary
Forms/Guidelines
FAQs
Resources
Contact Us

Ontario Guidelines for Economic Analysis of Pharmaceutical Products

Discussion and Purpose

It is important for manufacturers to constantly keep in mind that the guidelines presented in this document will allow them to move beyond the traditional simplistic "economic analysis" that simply compares the unit prices of their product with an older competitor. A full economic analysis allows manufacturers to represent the cost offsets and health benefits that are expected to result from using their product instead of an alternative. The purpose of providing the guidelines, and requiring that companies either present an economic analysis or justify its absence, is to provide the DQTC with better information to enable its members to judge the "value for the money" associated with each product under review.

It is intended that these guidelines incorporate considerable flexibility in their interpretation and application, while industry, academia, the DQTC and government increase their experience with, and expertise in, the techniques of economic analysis.

Accordingly, these guidelines, produced after considerable feedback on earlier drafts from industry, academia, and consultants (Detsky 1993), will almost certainly be revised in the future. When a national document is produced by the steering committee of the Canadian Collaborative Workshop on Pharmacoeconomics, the DQTC will review any differences between the documents. At the present time, it is anticipated that there will be no substantial differences in recommended methodologies, although there may be a difference in format. Manufacturers will be informed about the relationship between the documents when the DQTC has had the opportunity to review the final version of the national document.

Economic analyses will be reviewed with considerable flexibility, particularly over the next 2 years, while the DQTC continues to revise these guidelines as it gains experience, and as the science of measurement and analysis advances. Those preparing submissions should be encouraged to experiment with various approaches as part of the general development of this field, and to engage the DQTC in ongoing discussions about these efforts.

For more information
INFOline
Tel : 1-866-532-3161
(Toll-free in Ontario only)
TTY 1-800-387-5559
Hours of operation: 8:30am - 5:00pm
 
Go to top of page
|  return to main publications menu  |  return to program publications menu  |
|  home  |  central site  |  contact us  |  site map  |  français  |

This site maintained by the government of Ontario, Canada.